by Mette S van
Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge
Kemper, Vincent O Dezentjé, Irma M Oving, Aafke H Honkoop, Lidwine W Tick,
Agnes J van de Wouw, Caroline M Mandigers, Laurence J van Warmerdam, Jelle
Wesseling, Marie-Jeanne T Vrancken Peeters, Sabine C Linn, Gabe S Sonke, Dutch
Breast Cancer Research Group (BOOG)
The Lancet
Oncology: Volume 19, issue 12, P1630-1640, December 01, 2018
In view of the high
proportion of pathological complete responses recorded in both groups and the
fact that febrile neutropenia was more frequent in the anthracycline group,
omitting anthracyclines from neoadjuvant treatment regimens might be a
preferred approach in the presence of dual HER2 blockade in patients with early
HER2-positive breast cancer. Long-term follow-up is required to confirm these
results.
